CL2013000734A1 - Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico. - Google Patents

Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.

Info

Publication number: CL2013000734A1
Authority: CL; Chile
Prior art keywords: imidazol; substituted; composition; intraocular pressure; compounds derived
Prior art date: 2010-09-16

Application number

CL2013000734A

Other languages

English (en)

Inventor

Mohammed I Dibas

Daniel W Gil

Ken Chow

Liming Wang

Michael E Garst

John E Donello

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-16

Filing date

2013-03-18

Publication date

2013-11-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000734(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-18 Application filed by Allergan Inc filed Critical Allergan Inc

2013-11-08 Publication of CL2013000734A1 publication Critical patent/CL2013000734A1/es

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL2013000734A 2010-09-16 2013-03-18 Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico. CL2013000734A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US38337010P	2010-09-16	2010-09-16

Publications (1)

Publication Number	Publication Date
CL2013000734A1 true CL2013000734A1 (es)	2013-11-08

Family

ID=44675870

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
CL2013000735A CL2013000735A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2013000733A CL2013000733A1 (es)	2010-09-16	2013-03-18	Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.
CL2013000736A CL2013000736A1 (es)	2010-09-16	2013-03-18	Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.
CL2013000734A CL2013000734A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para bajar la presion intraocular; kit farmaceutico.

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
CL2013000735A CL2013000735A1 (es)	2010-09-16	2013-03-18	Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
CL2013000733A CL2013000733A1 (es)	2010-09-16	2013-03-18	Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.
CL2013000736A CL2013000736A1 (es)	2010-09-16	2013-03-18	Uso de prodrogas ester de [3-(1-(1h-imidazol-4-il)etil)-2-metil-fenil]metanol para preparar un medicamento util en el tratamiento de enfermedades de la retina tales como degeneracion macular humeda y seca, y retinopatia diabetica; y uso de la composicion que comprende a dichos compuestos.

Country Status (28)

Country	Link
US (9)	US8653123B2 (es)
EP (13)	EP3338777B1 (es)
JP (4)	JP2013537236A (es)
KR (7)	KR102139905B1 (es)
CN (5)	CN105412092B (es)
AR (4)	AR083018A1 (es)
AU (4)	AU2011301856C1 (es)
BR (4)	BR112013006355A2 (es)
CA (8)	CA3122745A1 (es)
CL (4)	CL2013000735A1 (es)
CY (3)	CY1121024T1 (es)
DK (9)	DK3348264T3 (es)
ES (10)	ES2593612T3 (es)
HU (5)	HUE048725T2 (es)
IL (4)	IL225278A (es)
MX (4)	MX2013003009A (es)
MY (4)	MY161607A (es)
NZ (1)	NZ608751A (es)
PL (7)	PL3050564T3 (es)
PT (7)	PT3050563T (es)
RU (4)	RU2612351C2 (es)
SG (4)	SG188572A1 (es)
SI (5)	SI3348264T1 (es)
TR (1)	TR201909249T4 (es)
TW (4)	TW201305116A (es)
UA (1)	UA112973C2 (es)
WO (4)	WO2012037453A1 (es)
ZA (4)	ZA201302194B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2752148A1 (en)	2009-02-13	2010-08-19	Daniel W. Gil	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
US8653123B2 (en) *	2010-09-16	2014-02-18	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
BR112014001501A2 (pt) *	2011-07-22	2017-02-14	Allergan Inc	moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho
CA2856507C (en)	2011-11-21	2017-03-21	Allergan, Inc.	Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en)	2014-11-28	2017-08-15	Samsung Electronics Co., Ltd.	Display screen or portion thereof with a graphical user interface
CN108310442B (zh) *	2017-01-17	2021-08-27	台北科技大学	眼科用组合物
KR102050506B1 (ko)	2017-06-20	2019-11-29	한국식품연구원	망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) *	2018-07-09	2021-03-23	成都倍特药业股份有限公司	一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
AU2019326633B2 (en) *	2018-08-24	2022-09-08	Adlai Nortye Biopharma Co., Ltd.	High activity sting protein agonist
CN117500497A (zh) *	2021-04-16	2024-02-02	Ads医疗有限责任公司	与毒蕈碱激动剂药偶联的α2肾上腺素能激动剂复合药
KR20230172529A (ko) *	2021-04-16	2023-12-22	에이디에스 테라퓨틱스 엘엘씨	무스칼린 작용제 약물과 접합된 알파2 아드레날린 작용제 복합 약물
AU2024217271A1 (en) *	2023-02-08	2025-09-18	Bausch + Lomb Ireland Limited	Alpha-2-adrenergic agonists for improving vision
WO2025179071A1 (en) *	2024-02-20	2025-08-28	Bausch + Lomb Ireland Limited	Sustained-release drug delivery compositions for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
US5459133A (en) *	1992-06-05	1995-10-17	Telor Ophthalmic Pharmaceuticals, Inc.	Methods and products for treating presbyopia
NZ276883A (en)	1993-11-15	1998-08-26	Schering Corp	1h-imidazol-4-yl)alkyl]benzene derivatives
US5474979A (en)	1994-05-17	1995-12-12	Allergan, Inc.	Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) *	1998-05-12	1999-11-17	Schwarz Pharma Ag	Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) *	2000-07-14	2004-10-28	Allergan, Inc.	Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en)	2001-05-03	2002-12-26	Allergan Sales Inc.	Compositions having enhanced pharmacokinetic characteristics
ES2311847T3 (es) *	2003-05-27	2009-02-16	Societe De Conseils De Recherches Et D'applications Scientifiques ( S.C.R.A.S.)	Nuevos derivados de imidazoles, su prepracion y su utilizacion como medicamento.
US7439241B2 (en) *	2003-05-27	2008-10-21	Galderma Laboratories, Inc.	Compounds, formulations, and methods for treating or preventing rosacea
KR20060052809A (ko) *	2003-07-14	2006-05-19	코닌클리케 필립스 일렉트로닉스 엔.브이.	프로젝션 디바이스
EP1663311A2 (en)	2003-09-12	2006-06-07	Allergan, Inc.	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) *	2004-04-30	2005-11-03	Allergan, Inc.	Sustained release intraocular implants and methods for treating ocular vasculopathies
ES2424644T3 (es)	2004-05-25	2013-10-07	Galderma Pharma S.A.	Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel
US20050277584A1 (en)	2004-06-09	2005-12-15	Allergan, Inc.	Pharmaceutical compositions comprising cyclosporins
EP1797043A1 (en)	2004-09-24	2007-06-20	Allergan, Inc.	4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en)	2005-05-10	2011-04-26	Allergan, Inc.	Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en)	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US7297679B2 (en)	2005-07-13	2007-11-20	Allergan, Inc.	Cyclosporin compositions
US20070082070A1 (en) *	2005-10-11	2007-04-12	Stookey Evangeline L	Treating skin disorders
US7902247B2 (en)	2008-01-09	2011-03-08	Allergan, Inc.	Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2010091209A1 (en)	2009-02-06	2010-08-12	Allergan, Inc.	Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
CA2752148A1 (en) *	2009-02-13	2010-08-19	Daniel W. Gil	Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) *	2009-11-19	2013-03-12	Galderma Laboratories, L.P.	Method for treating psoriasis
US8653123B2 (en) *	2010-09-16	2014-02-18	Allergan, Inc.	Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

2011
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en not_active Ceased
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Active
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Withdrawn
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en not_active Ceased
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en not_active Ceased
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active Active
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active Active
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko active Active
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active Active
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active Active
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en not_active Ceased
2013
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown

Also Published As

Publication number	Publication date
EP3078376A1 (en)	2016-10-12
HK1185538A1 (zh)	2014-02-21
DK3050564T3 (da)	2019-11-25
US20120142746A1 (en)	2012-06-07
US20120122945A1 (en)	2012-05-17
BR112013006320A2 (pt)	2016-06-21
WO2012037490A1 (en)	2012-03-22
ZA201302193B (en)	2013-11-27
ZA201302194B (en)	2013-11-27
KR102104760B1 (ko)	2020-04-27
TW201305116A (zh)	2013-02-01
EP3053576B1 (en)	2018-05-16
NZ608751A (en)	2015-04-24
EP3636263A1 (en)	2020-04-15
AU2011301932C1 (en)	2016-09-01
ES2904479T3 (es)	2022-04-05
PT2616069T (pt)	2016-12-06
CN103200941B (zh)	2015-12-16
PT3050563T (pt)	2018-10-01
AU2011301856C1 (en)	2016-09-08
US8492422B2 (en)	2013-07-23
HK1185541A1 (zh)	2014-02-21
MY161607A (en)	2017-04-28
EP2616066A1 (en)	2013-07-24
AU2011301901B2 (en)	2016-02-11
KR20200044147A (ko)	2020-04-28
ES2687420T3 (es)	2018-10-25
EP3348264B1 (en)	2020-01-01
CA2811559A1 (en)	2012-03-22
US20120149746A1 (en)	2012-06-14
UA112973C2 (uk)	2016-11-25
CA3116249A1 (en)	2012-03-22
EP2616066B1 (en)	2016-07-13
KR20190022895A (ko)	2019-03-06
DK3078376T3 (da)	2019-06-24
CN103221045A (zh)	2013-07-24
EP2616069A1 (en)	2013-07-24
MX2013003009A (es)	2013-06-28
RU2013116405A (ru)	2014-10-27
MY168763A (en)	2018-12-04
AR083019A1 (es)	2013-01-23
WO2012037499A1 (en)	2012-03-22
CL2013000735A1 (es)	2013-11-29
KR20140005154A (ko)	2014-01-14
ZA201302291B (en)	2013-11-27
EP3053576A1 (en)	2016-08-10
TWI591058B (zh)	2017-07-11
IL225278A0 (en)	2013-06-27
ES2613509T3 (es)	2017-05-24
IL225278A (en)	2015-11-30
EP3636263B1 (en)	2021-11-03
SG188570A1 (en)	2013-04-30
ES2684055T3 (es)	2018-10-01
US20160354346A1 (en)	2016-12-08
EP2616068A1 (en)	2013-07-24
SG188572A1 (en)	2013-04-30
US8492557B2 (en)	2013-07-23
TW201240661A (en)	2012-10-16
KR20140003407A (ko)	2014-01-09
TW201240662A (en)	2012-10-16
PL3050564T3 (pl)	2020-06-01
CA2812197C (en)	2024-01-02
US8653123B2 (en)	2014-02-18
CN103209694A (zh)	2013-07-17
PT3338777T (pt)	2020-05-06
DK3050563T3 (en)	2018-08-13
AR083020A1 (es)	2013-01-23
HK1185539A1 (zh)	2014-02-21
JP2013540749A (ja)	2013-11-07
PT3053576T (pt)	2018-10-08
PL2616068T3 (pl)	2016-11-30
IL225280A0 (en)	2013-06-27
KR101840501B1 (ko)	2018-05-04
AU2011301932B2 (en)	2016-02-25
CN105412092B (zh)	2020-11-17
EP2616067A1 (en)	2013-07-24
EP2616068B1 (en)	2016-07-13
HK1185540A1 (en)	2014-02-21
AU2011301856A1 (en)	2013-05-02
ES2593612T3 (es)	2016-12-12
PL2616069T3 (pl)	2017-04-28
SI3348264T1 (sl)	2020-07-31
DK3636263T3 (da)	2022-01-10
KR101952457B1 (ko)	2019-02-26
PL3348264T3 (pl)	2020-08-24
WO2012037484A1 (en)	2012-03-22
KR20130114140A (ko)	2013-10-16
AU2011301901A1 (en)	2013-05-02
IL225282A0 (en)	2013-06-27
BR112013006320B1 (pt)	2022-08-30
EP3078376B1 (en)	2019-03-27
CA2812195A1 (en)	2012-03-22
US20130296394A1 (en)	2013-11-07
HUE047476T2 (hu)	2020-04-28
EP3050563B1 (en)	2018-05-09
US8501796B2 (en)	2013-08-06
EP3050564B1 (en)	2019-09-04
US20140057958A1 (en)	2014-02-27
SI3338777T1 (sl)	2020-08-31
MX2013003004A (es)	2013-06-28
DK2616068T3 (en)	2016-08-29
AU2011301847B2 (en)	2016-02-11
CN103200941A (zh)	2013-07-10
HUE039090T2 (hu)	2018-12-28
ES2607084T3 (es)	2017-03-29
KR20200091507A (ko)	2020-07-30
CY1121024T1 (el)	2019-12-11
HUE048725T2 (hu)	2020-09-28
BR112013006352A2 (pt)	2016-06-28
SI3050563T1 (sl)	2018-10-30
DK3348264T3 (da)	2020-03-23
KR102354097B1 (ko)	2022-01-20
EP2616069B1 (en)	2016-11-16
CA2812197A1 (en)	2012-03-22
CL2013000736A1 (es)	2013-07-12
TW201305117A (zh)	2013-02-01
WO2012037453A1 (en)	2012-03-22
MY173846A (en)	2020-02-24
PT3348264T (pt)	2020-04-02
SI3053576T1 (sl)	2018-11-30
JP2013537236A (ja)	2013-09-30
CN105412092A (zh)	2016-03-23
EP3050564A1 (en)	2016-08-03
RU2013116541A (ru)	2014-10-27
MX2013003002A (es)	2013-06-28
PL3338777T3 (pl)	2020-07-13
CY1122809T1 (el)	2021-05-05
EP3338777A1 (en)	2018-06-27
ES2781681T3 (es)	2020-09-04
CL2013000733A1 (es)	2013-08-23
CA3077732A1 (en)	2012-03-22
ES2760920T3 (es)	2020-05-18
JP6073229B2 (ja)	2017-02-01
CA2812191A1 (en)	2012-03-22
HUE049573T2 (hu)	2020-10-28
JP2013541527A (ja)	2013-11-14
ZA201302288B (en)	2013-11-27
PL3053576T3 (pl)	2018-11-30
AU2011301847A1 (en)	2013-05-02
EP2616067B1 (en)	2016-05-18
HK1257416A1 (en)	2019-10-18
KR101840500B1 (ko)	2018-03-20
PL3050563T3 (pl)	2018-12-31
AU2011301932A1 (en)	2013-05-02
EP3338777B1 (en)	2020-02-05
SG188573A1 (en)	2013-04-30
MX2013003008A (es)	2013-06-28
EP3348264A1 (en)	2018-07-18
EP3659600A1 (en)	2020-06-03
US20130289088A1 (en)	2013-10-31
KR102139905B1 (ko)	2020-07-31
CN103200942A (zh)	2013-07-10
TR201909249T4 (tr)	2019-07-22
JP6045495B2 (ja)	2016-12-14
CA3079450A1 (en)	2012-03-22
MY191369A (en)	2022-06-20
DK3053576T3 (en)	2018-08-20
CY1122958T1 (el)	2021-10-29
AR083017A1 (es)	2013-01-23
BR112013006362A2 (pt)	2016-06-28
EP3698789A1 (en)	2020-08-26
US20120136036A1 (en)	2012-05-31
DK3338777T3 (da)	2020-04-20
HUE038698T2 (hu)	2018-11-28
US20150148394A1 (en)	2015-05-28
RU2612351C2 (ru)	2017-03-07
BR112013006355A2 (pt)	2016-06-28
SG188571A1 (en)	2013-04-30
CA2812191C (en)	2021-04-13
IL225281A0 (en)	2013-06-27
JP2013537237A (ja)	2013-09-30
US8853251B2 (en)	2014-10-07
PT3050564T (pt)	2019-12-11
SI3050564T1 (sl)	2020-02-28
CA3122745A1 (en)	2012-03-22
EP3050563A1 (en)	2016-08-03
ES2788051T3 (es)	2020-10-20
PT2616068T (pt)	2016-09-13
KR20130105658A (ko)	2013-09-25
RU2013116763A (ru)	2014-10-27
AR083018A1 (es)	2013-01-23
ES2737230T3 (es)	2020-01-10
RU2013116403A (ru)	2014-10-27
DK2616069T3 (en)	2016-12-19

Publication	Publication Date	Title
BR112014001255A2 (pt)	2017-02-21	composto, uso de um composto, combinação, e, composição farmacêutica
BR112014013760A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
GT201400136A (es)	2016-02-15	Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
BR112014005669A2 (pt)	2017-04-04	composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt)	2018-08-14	composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
CO6900149A2 (es)	2014-03-20	Una composición farmacéutica que comprende los fitocanabinoides canabidivarina (cbdv) y canabidiol (cbd)
BR112013018877A2 (pt)	2016-10-04	composições farmacêuticas que compreendem anticorpos humanos para pcsk9
BR112014007134A2 (pt)	2017-12-19	usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
BR112014003802A2 (pt)	2017-06-13	composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
CL2014001399A1 (es)	2014-11-03	Compuestos de reversion anticoagulante; composicion farmaceutica y el uso de los mismos para revertir el efecto anticoagulante de un inhibidor de la coagulacion.
BR112015000420A2 (pt)	2017-06-27	composto, composição farmacêutica, e, uso de um composto
CL2013001947A1 (es)	2014-05-23	Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
UY32153A (es)	2011-04-29	Inhibidores de piridomidinona de pi13ka(alfa) y mtor
BR112012001998A2 (pt)	2017-01-31	solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
MX2013011336A (es)	2013-12-16	Composiciones farmaceuticas intranasales de benzodiazepina.
UY31788A (es)	2009-12-14	Formulación farmacéutica sólida con liberación retardada
BR112014013177A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BR112014013178A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BR112014002845A2 (pt)	2017-02-21	composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
HN2010001537A (es)	2013-05-06	Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CL2016001663A1 (es)	2017-01-06	Uso del compuesto de fórmula (xxi), que sirve para preparar una fragancia
CO6920289A2 (es)	2014-04-10	Composición farmacéutica oftalmológica tópica que contiene regorafenib.
BRPI1013597A2 (pt)	2016-04-19	seringa para uso único